40
Participants
Start Date
July 1, 2017
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2027
Defibrotide
defibrotide will be given prophylactically prior to AlloSCT to determine if it decreases the incidence of SOS in this high risk population, and determine that it is safe and feasible to give along with myeloimmunoablative therapy and allogeneic transplant.
RECRUITING
New York Medical College, Valhalla
RECRUITING
Medical College of Wisconsin, Milwaukee
RECRUITING
University of California Los Angeles, Los Angeles
RECRUITING
University of Florida, Gainesville
Lead Sponsor
University of California, Los Angeles
OTHER
Medical College of Wisconsin
OTHER
Tufts Medical Center
OTHER
Baylor College of Medicine
OTHER
Johns Hopkins University
OTHER
Dana-Farber Cancer Institute
OTHER
Children's Hospital Los Angeles
OTHER
New York Medical College
OTHER